Qiagen NV (QGEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Qiagen NV stock (QGEN) is currently trading at $40.63. Qiagen NV PE ratio is 19.50. Qiagen NV PS ratio (Price-to-Sales) is 3.92. Analyst consensus price target for QGEN is $55.23. WallStSmart rates QGEN as Moderate Buy.
- QGEN PE ratio analysis and historical PE chart
- QGEN PS ratio (Price-to-Sales) history and trend
- QGEN intrinsic value — DCF, Graham Number, EPV models
- QGEN stock price prediction 2025 2026 2027 2028 2029 2030
- QGEN fair value vs current price
- QGEN insider transactions and insider buying
- Is QGEN undervalued or overvalued?
- Qiagen NV financial analysis — revenue, earnings, cash flow
- QGEN Piotroski F-Score and Altman Z-Score
- QGEN analyst price target and Smart Rating
Qiagen NV
📊 No data available
Try selecting a different time range
QGEN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Qiagen NV (QGEN)
QGEN trades at a significant discount to its Graham intrinsic value of $85.35, offering a 40% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Qiagen NV (QGEN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, eps growth. Concerns around revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Qiagen NV (QGEN) Key Strengths (6)
Keeps $20 of every $100 in revenue as net profit
76.43% of shares held by major funds and institutions
Good growth relative to its price
Strong operational efficiency: $27 kept per $100 revenue
Strong earnings growth at 21.90% per year
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Qiagen NV (QGEN) Areas to Watch (4)
Revenue growing slowly at 3.70% annually
Moderate profitability with room for improvement
Revenue is fairly priced at 3.92x sales
Fairly priced relative to book value
Qiagen NV (QGEN) Detailed Analysis Report
Overall Assessment
This company scores 69/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.5/10) while 4 fall into concern territory (avg 4.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Profit Margin, Institutional Own., PEG Ratio. Valuation metrics including PEG Ratio (1.00) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 27.40%, Profit Margin at 20.30%. Growth metrics are encouraging with EPS Growth at 21.90%.
The Bear Case
The primary concerns are Revenue Growth, Return on Equity, Price/Sales. Some valuation metrics including Price/Sales (3.92), Price/Book (2.17) suggest expensive pricing. Growth concerns include Revenue Growth at 3.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 11.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 3.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Profit Margin, Institutional Own.) and negatives (Revenue Growth, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
QGEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
QGEN's Price-to-Sales ratio of 3.92x trades 17% below its historical average of 4.7x (41th percentile). The current valuation is 61% below its historical high of 10.04x set in Oct 2007, and 54% above its historical low of 2.55x in Nov 2011. Over the past 12 months, the PS ratio has compressed from ~4.9x as trailing revenue scaled faster than the stock price.
Compare QGEN with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Qiagen NV (QGEN) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Qiagen NV is a strong growth company balancing expansion with improving profitability. Revenue reached 2.1B with 370% growth year-over-year. Profit margins are strong at 20.3%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 370% YoY, reaching 2.1B. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
ROE of 1160.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Qiagen NV maintain 370%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Qiagen NV.
Bottom Line
Qiagen NV offers an attractive blend of growth (370% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Qiagen NV(QGEN)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.